(Q42947657)

11 November 2017

title

Risk of skeletal-related events in patients with advanced prostate cancer treated with pamidronate or zoledronic acid (English)

1 reference

11 November 2017

Risk of Skeletal-Related Events in Patients with Advanced Prostate Cancer Treated with Pamidronate or Zoledronic Acid (English)

1 reference

16 June 2024

author

Joanne E. Schottinger

4

object named as

Joanne E Schottinger

1 reference

11 November 2017

James Chan

3

1 reference

11 November 2017

Michele M. Spence

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20682850

16 June 2024

Rita L. Hui

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20682850

16 June 2024

language of work or name

English

0 references

publication date

3 August 2010

1 reference

full work available at URL

11 November 2017

http://www.theannals.com/cgi/content/abstract/44/9/1384

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20682850

http://journals.sagepub.com/doi/pdf/10.1345/aph.1P152

16 June 2024

1 reference

Annals of Pharmacotherapy

16 June 2024

published in

1 reference

11 November 2017

volume

44

1 reference

11 November 2017

issue

9

1 reference

11 November 2017

page(s)

1384-1388

1 reference

Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer

11 November 2017

cites work

1 reference

Preserving bone health in patients with hormone-sensitive prostate cancer: the role of bisphosphonates

21 January 2018

1 reference

Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer

21 January 2018

1 reference

Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer

21 January 2018

1 reference

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma

21 January 2018

1 reference

Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer

21 January 2018

1 reference

Extended use of intravenous bisphosphonate therapy for the prevention of skeletal complications in patients with cancer

21 January 2018

1 reference

Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws

21 January 2018

1 reference

American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer

21 January 2018

1 reference

American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer

21 January 2018

1 reference

Bisphosphonates for advanced prostate cancer

21 January 2018

1 reference

The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy

21 January 2018

2

1 reference

Outcomes of patients with prostate cancer receiving zoledronic acid or pamidronate for prevention of skeletal-related events

16 June 2024

10

1 reference

16 June 2024

Identifiers

DOI

10.1345/APH.1P152

1 reference

11 November 2017

1 reference